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Table 1. Data on 39 respiratory syncytial virus (RSV)–infected pediatric patients with
cancer.
Characteristic Value
Malignancy
Leukemia 25 (64)
Acute lymphoblastic leukemia 17 (44)
Acute myeloid leukemia 8 (21)
Non-Hodgkin lymphoma 5 (13)
Solid tumor (except CNS tumor) 2 (5)
CNS tumor 2 (5)
Other malignancy 2 (5)
Receipt of solid-organ transplant 3 (8)
Leukocyte count at diagnosis,a 109 leukocytes/L
Median (range) 3.8 (300–62,500)
IQR 1.9–5.5
Neutropeniab at diagnosisa 6 (15)
Body temperature
138.5C 21 (54)
139C 14 (36)
Tachypnea at diagnosisa 25 (64)
Hypoxemiac at diagnosisa 5 (13)
Underwent radiologic examination of the chest 30 (77)
Pneumonia confirmed by radiologic examination of the chest 10 (26)
Received antibiotic treatment 26 (67)
Received supplemental oxygen 17 (44)
Admitted to pediatric intensive care unit 5 (13)
Received mechanical ventilation 1 (3)
Hospitalization attributed to RSV infection, inpatient days
Median (range) 7 (2–35)
IQR 5–11
Mortality, %
All cause 5
Related to RSV infection 0
NOTE. Data are no. (%) of patients, unless otherwise indicated. There were 17 male patients and 22
female patients. The median age at diagnosis of RSV infection was 33 months (interquartile range [IQR],
20–72 months; range, 4–217 months).
a Diagnosis of RSV infection.
b Leukocyte count leukocytes/L and no differential blood cell count available or neutrophil9! 1.010
count neutrophils/L.9! 0.510
c Transcutaneously measured hemoglobin saturation (tcSO2) level !94%.
monoclonal antibody [11]—should be de-
bated for cases of RSV infection.
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Respiratory Syncytial
Virus Infection in
Immunocompromised
Patients Revisited
To the Editor—We read with great in-
terest the letter from Simon et al. [1] re-
porting respiratory syncytial virus (RSV)
infection in 39 immunocompromised pe-
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diatric patients (median age, 33 months),
including patients with cancer and recip-
ients of solid-organ transplants. Although
none underwent hematopoietic stem cell
transplantation, 30 patients appeared to
have underlying hematological disease
comparable to that in our 32 adult patients
[2]. The authors report that none of the
children died of RSV-related causes, al-
though only 3 received treatment with oral
ribavirin (2 patients) or intravenous pa-
livizumab (1 patient).
The reason for the striking difference
between the study by Simon et al. [1] and
our study [2] is unclear and might reflect
the recovery competence of children [3].
It seems to us that a key difference could
reside in the delaying of chemotherapy for
25 of the pediatric patients. In addition,
80% of our case patients were hemato-
poietic stem cell transplant recipients [2].
In fact, RSV-attributed mortality was sig-
nificantly associated with pre-engraftment
and with 2 criteria of severe immuno-
deficiency, such as receipt of hematopoi-
etic stem cell transplant within the pre-
vious 6 months, T cell or B cell depletion
within the previous 3 months, graft-ver-
sus-host disease of grade 2, leukopenia
(leukocyte count, 2.0109 cells/L),
lymphopenia (lymphocyte count, 0.1
109 cells/L), or hypogammaglobuline-
mia (Ig level, 6.5 g/L). Conversely, pa-
tients with moderate immunodeficiency
had a favorable course. We noted that 3
of our patients with severe immunodefi-
ciency survived RSV infection without any
intervention [2]. These 3 patients all had
a lack of T cell depletion, the absence of
lymphopenia or leukopenia, and the pres-
ence of graft-versus-host disease of grade
2. Although the role of severe immu-
nodeficiency in risk stratification and
treatment requires validation in prospec-
tive clinical studies, it would be important
to know the potential use of these criteria
for immunocompromised children [1, 3].
Simon et al. [1] indicated that 10 patients
had radiological evidence of pneumonia,
5 patients were admitted to the intensive
care unit, and only 1 required mechanical
ventilation. This is in contrast to our study,
in which lower respiratory tract infection
was significantly associated with RSV-at-
tributable mortality in patients with severe
immunodeficiency [2].
The retrospective report by de Font-
brune et al. [4] concluded that adminis-
tration of palivizumab was costly but was
not associated with any discernable ben-
efit. Among 18 patients with upper respi-
ratory tract infection, one-half of whom
received treatment with palivizumab, pro-
gression to lower respiratory tract infec-
tion was observed in 56% in both groups.
RSV-associated death occurred in 3 (33%)
of the 9 patients in the palivizumab-
treated group and in 1 (11%) of the 9
patients in the untreated group. However,
palivizumab was preferentially adminis-
tered to recipients at a presumably higher
risk, such as cord blood transplant recip-
ients (6 [67%] of 9 in the treated group
vs. 0 [0%] of 9 in the untreated group)
and patients who had RSV infection
within 30 days after hematopoietic stem
cell transplantation (8 [89%] of 9 in the
treated group vs. 3 [33%] of 9 in the un-
treated group).
Regarding the use of ribavirin, Simon
et al. [1] point out that oral (systemic)
administration is simpler than aerosoli-
zation, particularly for pediatric patients.
We found that oral ribavirin at a maxi-
mum daily dose of 1800 mg was generally
well tolerated, but reversible hemolysis
was observed in ∼20% of patients [2].
Therefore, we agree with Simon and col-
leagues that prospective, multicenter stud-
ies are needed to identify effective antiviral
treatments for RSV infection among im-
munocompromised patient groups, for
which the new high-affinity monoclonal
motavizumab, as well as systemic ribavi-
rin, could be an option.
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Transmission of Adenovirus
Serotype 14 in the Health
Care Setting
To the Editor—In the 1 February 2008
issue of Clinical Infectious Diseases, Louie
et al. [1] described a cluster of severe re-
spiratory illnesses caused by adenovirus
serotype 14 (Ad14). Two children, both
requiring high-frequency oscillatory ven-
tilation (HFOV), were admitted to adja-
cent beds in the intensive care unit; Ad14
infection was diagnosed during the course
of hospitalization for both patients. Louie
et al. [1] speculated that 1 of these cases
may have been acquired nosocomially. We
describe a cluster of health care workers
(HCWs) infected with adenovirus in as-
sociation with caring for a critically ill pa-
tient with Ad14 infection, to highlight the
